ClarificationAug 7, 2026, 04:26 PM
Certara Corrects Divested Business 2025 Adj. EBITDA to $23M
AI Summary
Certara, Inc. issued a clarification regarding a misstatement made during its second quarter 2026 earnings conference call and presentation. The company corrected the 2025 adjusted EBITDA figure for its recently divested Regulatory and Medical Writing business. While initially quoted as approximately $17 million excluding unallocated overhead, the correct figure, representing EBITDA excluding corporate expenses remaining with Certara, is approximately $23 million. This clarification does not affect previously reported financial results, year-over-year comparisons, or the company's 2026 Financial Outlook.
Key Highlights
- Certara clarified a misstatement regarding the 2025 adjusted EBITDA of its divested Regulatory and Medical Writing business.
- Initial statement on Q2 2026 earnings call and presentation quoted approximately $17 million (excluding unallocated overhead costs).
- The correct reference should have been approximately $17 million (including unallocated overhead costs).
- The actual 2025 adjusted EBITDA for the divested business, excluding corporate expense remaining with Certara, is approximately $23 million.
- An updated version of the Q2 2026 earnings presentation has been posted to the company's website.
- The clarification has no impact on previously reported financial results or year-over-year comparisons.
- The company's 2026 Financial Outlook remains unchanged by this clarification.
Price Impact
More from CERT